Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2019

View Archived Issues

Targeting lymph node stage may nip metastases in the bud

Genome editing used to create models of GM1-gangliosidosis and Morquio syndrome type B

Free radicals can benefit the brain

Urethral macrophages are HIV reservoir

Xiamen University describes triggering receptor expressed on myeloid cells 2 polypeptides

Rho-associated protein kinase 1/2 inhibitors disclosed by Kadmon

Curigin patents nucleic acid molecules inhibiting MTOR and AR gene expression

Beijing Sanyou Liheze Biological Technology describes anticoagulant fusion protein

HDAC3 is a novel therapeutic target for ischemic stroke

Results presented from phase I/II CHAMPIONS study of SB-913

New biomarkers discovered tied to intracranial aneurysm

ADAR1-editing of cell-cycle-regulatory miRNAs is involved in progenitor malignant transformation

Tumor-specific near-infrared agent targeting PSMA for fluorescence-guided surgery in prostate cancer

Sterol regulatory element binding protein as a potential target for broad-spectrum antiviral agents

Viral-mediated TMBIM6 gene delivery protects against neonatal hypoxic ischemia

European Commission extends marketing authorization for Adcetris

Sprycel receives European approval in pediatric patients with newly diagnosed Ph+ ALL

Patient enrollment ongoing in phase I study of SER-401 in combination with nivolumab

FDA approves IND for ABBV-0805 for Parkinson's disease

Ascendis announces phase II trial of TransCon PTH to treat hypoparathyroidism

Increased miR-9 levels in CSF found to be a poor prognostic factor after subarachnoid hemorrhage

Bicycle awarded contract to identify novel inhibitors of PBPs of key bacterial pathogens

3SBio and Verseau collaborate in immuno-oncology

STELLAR-4 trial of selonsertib in compensated cirrhosis due to NASH does not meet week 48 endpoint

Redx's preclinical ROCK-II compound suppresses collagen deposition and pathways linked to fibrosis

Aduro doses first patient with ADU-S100 and Yervoy for melanoma in phase I trial

New phase III trial in China studies HC-1119 for metastatic CRPC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...